8-K//Current report
Bausch Health Companies Inc. 8-K
Accession 0000885590-25-000059
$BHCCIK 0000885590operating
Filed
Dec 28, 7:00 PM ET
Accepted
Dec 29, 7:32 AM ET
Size
264.9 KB
Accession
0000885590-25-000059
Research Summary
AI-generated summary of this filing
Bausch Health Issues $1.6B of 10.00% Senior Secured Notes Due 2032
What Happened
- Bausch Health Companies Inc. and its indirect wholly owned subsidiary 1261229 B.C. Ltd. completed exchange offers (per a Nov 24, 2025 Exchange Offer Memorandum) to swap outstanding 4.875% and 11.00% Senior Secured Notes due 2028 for new 10.00% Senior Secured Notes due 2032.
- The Issuer issued $1.6 billion aggregate principal amount of New Notes on the Settlement Date (as documented in a Second Supplemental Indenture dated December 26, 2025). The New Notes form a single, fungible series with the Issuer’s existing $4.4 billion of 10.00% Senior Secured Notes due 2032 (the “Existing Numberco Notes”).
Key Details
- Amount issued: $1.6 billion of New 10.00% Senior Secured Notes due 2032.
- Interest accrual: New Notes accrue interest from October 15, 2025.
- Security: The notes are secured by a first-priority lien on substantially all assets of the Issuer and guarantors, including a pledge of the Issuer’s equity in Bausch + Lomb. After issuance, the Issuer holds 211,963,893 common shares of Bausch + Lomb (about 60% of outstanding shares) pledged as collateral (an additional 26,495,472 shares were transferred and pledged at issuance).
- Registration and trading: The New Notes are unregistered under the Securities Act and were issued under Rule 144A and Regulation S; Reg S notes have separate CUSIP/ISIN identifiers for at least a 40-day restricted period before matching the Existing Notes’ identifiers.
Why It Matters
- This transaction extends the company’s secured debt maturity profile from 2028 to 2032 and increases the amount of 10.00% secured notes outstanding (now fungible with an existing $4.4B series), changing Bausch Health’s near-term debt obligations.
- The notes are secured by a pledged majority stake in Bausch + Lomb (~60%), which is material collateral supporting these obligations and could affect recovery priorities for creditors relative to other stakeholders.
- Because the New Notes are not registered, secondary market liquidity will be limited to exempt trading channels (Rule 144A / Reg S), which matters for investors who trade debt securities.
Documents
- 8-Kbhc-20251226.htmPrimary
8-K
- EX-4.2exhibit42-126numbercox2025.htm
EX-4.2
- EX-101.SCHbhc-20251226.xsd
XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
- EX-101.LABbhc-20251226_lab.xml
XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
- EX-101.PREbhc-20251226_pre.xml
XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
- XMLR1.htm
IDEA: XBRL DOCUMENT
- XMLShow.js
IDEA: XBRL DOCUMENT
- XMLreport.css
IDEA: XBRL DOCUMENT
- XMLFilingSummary.xml
IDEA: XBRL DOCUMENT
- JSONMetaLinks.json
IDEA: XBRL DOCUMENT
- ZIP0000885590-25-000059-xbrl.zip
IDEA: XBRL DOCUMENT
- XMLbhc-20251226_htm.xml
IDEA: XBRL DOCUMENT
Issuer
Bausch Health Companies Inc.
CIK 0000885590
Entity typeoperating
IncorporatedNJ
Related Parties
1- filerCIK 0000885590
Filing Metadata
- Form type
- 8-K
- Filed
- Dec 28, 7:00 PM ET
- Accepted
- Dec 29, 7:32 AM ET
- Size
- 264.9 KB